RhumbLine Advisers’s Lyell Immunopharma LYEL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-11,785
| Closed | -$127K | – | 4210 |
|
|
2025
Q1 | $127K | Sell |
11,785
-2,271
| -16% | -$24.4K | ﹤0.01% | 3305 |
|
|
2024
Q4 | $180K | Buy |
14,056
+367
| +3% | +$4.7K | ﹤0.01% | 3250 |
|
|
2024
Q3 | $378K | Buy |
13,689
+652
| +5% | +$18K | ﹤0.01% | 2893 |
|
|
2024
Q2 | $378K | Sell |
13,037
-872
| -6% | -$25.3K | ﹤0.01% | 2853 |
|
|
2024
Q1 | $620K | Buy |
13,909
+365
| +3% | +$16.3K | ﹤0.01% | 2526 |
|
|
2023
Q4 | $526K | Buy |
13,544
+103
| +0.8% | +$4K | ﹤0.01% | 2627 |
|
|
2023
Q3 | $395K | Sell |
13,441
-304
| -2% | -$8.94K | ﹤0.01% | 2750 |
|
|
2023
Q2 | $874K | Buy |
13,745
+142
| +1% | +$9.03K | ﹤0.01% | 2366 |
|
|
2023
Q1 | $642K | Buy |
13,603
+442
| +3% | +$20.9K | ﹤0.01% | 2318 |
|
|
2022
Q4 | $913K | Sell |
13,161
-225
| -2% | -$15.6K | ﹤0.01% | 2173 |
|
|
2022
Q3 | $1.96M | Buy |
13,386
+901
| +7% | +$132K | ﹤0.01% | 1773 |
|
|
2022
Q2 | $1.63M | Buy |
12,485
+4,916
| +65% | +$641K | ﹤0.01% | 1884 |
|
|
2022
Q1 | $764K | Buy |
7,569
+6,404
| +550% | +$646K | ﹤0.01% | 2243 |
|
|
2021
Q4 | $180K | Buy |
1,165
+321
| +38% | +$49.6K | ﹤0.01% | 2856 |
|
|
2021
Q3 | $250K | Buy |
+844
| New | +$250K | ﹤0.01% | 2839 |
|